Form 8-K - Current report:
SEC Accession No. 0001193125-25-210068
Filing Date
2025-09-22
Accepted
2025-09-22 08:11:03
Documents
13
Period of Report
2025-09-22
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d937976d8k.htm   iXBRL 8-K 27642
2 EX-99.1 d937976dex991.htm EX-99.1 9545
  Complete submission text file 0001193125-25-210068.txt   152319

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA advm-20250922.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE advm-20250922_lab.xml EX-101.LAB 17234
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE advm-20250922_pre.xml EX-101.PRE 10811
16 EXTRACTED XBRL INSTANCE DOCUMENT d937976d8k_htm.xml XML 3516
Mailing Address 100 CARDINAL WAY REDWOOD CITY CA 94063
Business Address 100 CARDINAL WAY REDWOOD CITY CA 94063 (650) 649-1004
Adverum Biotechnologies, Inc. (Filer) CIK: 0001501756 (see all company filings)

EIN.: 205258327 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36579 | Film No.: 251328484
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)